Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.52 |
| ▸ | ACKR3 | P25106 | 3/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.48 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | JAK1 | P23458 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | STS | P08842 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | AKT1 | P31749 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26998993 | 0.95 | SIGMAR1 (0.50) | SIGMAR1ACKR3CHRM2CHRM4CHRM1 | |
| SCHEMBL30380434 | 0.90 | SIGMAR1 (0.51) | SIGMAR1ACKR3CHRM2CHRM4CHRM1 | |
| SCHEMBL7971782 | 0.84 | SIGMAR1 (0.69) | SIGMAR1ACKR3 | |
| SCHEMBL16334863 | 0.82 | NAMPT (0.54) | SIGMAR1CHRM3NAMPTLMNA | |
| SCHEMBL21997547 | 0.81 | ACKR3 (0.48) | SIGMAR1ACKR3CHRM2CHRM4CHRM1 | |
| SCHEMBL3712707 | 0.81 | MEN1 (0.59) | SIGMAR1ACKR3CHRM2CHRM4CHRM1 | |
| SCHEMBL21070919 | 0.80 | ACKR3 (0.43) | SIGMAR1ACKR3CHRM2CHRM4CHRM1 | |
| SCHEMBL22609490 | 0.80 | ACKR3 (0.43) | SIGMAR1ACKR3CHRM2CHRM4CHRM1 | |
| SCHEMBL27379853 | 0.80 | JAK2 (0.52) | JAK2JAK1STS | |
| SCHEMBL31511550 | 0.80 | STS (0.54) | JAK2JAK1STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3013824-B1 | CARBOLINE COMPOUNDS USABLE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | ALZPROTECT (FR) | 2018-05-16 | — | — | EP | disclosed |
| US-9714245-B2 | Carboline compounds usable in the treatment of neurodegenerative diseases | ALZPROTECT (FR) | 2017-07-25 | — | — | US | disclosed |
| US-20160152610-A1 | Carboline Compounds Usable in The Treatment of Neurodegenerative Diseases | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2016-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160152610-A1 | Carboline Compounds Usable in The Treatment of Neurodegenerative Diseases | SNCA, PARK7, HTT | SIGMAR1 923/4885ACKR3 1309/4885CHRM2 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.